Palantir Technologies (NASDAQ:PLTR) has been described as the best pure-play stock in artificial intelligence. The market ...

On November 3, 2024, Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking's stock price to ...

VK2735 is a novel drug that targets glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This combination improves metabolic benefits for conditions ...

The recent data from Novo Nordisk’s Phase 3b trials highlighted the potential advantages of Viking’s VK2735. Pantginis emphasizes that VK2735, a dual GLP-1/GIP receptor agonist, may ...

VK2735 is a novel drug that targets glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This combination improves metabolic benefits for conditions ...

[Click here for information about joining the class action] On November 3, 2024, Viking released positive trial data for VK2735, the Company's anti-obesity drug, as part of a presentation at the ...

He said the company has enough supply of the subcutaneous formulation of its lead product, VK2735, to complete Phase 3 testing, and enough of the oral formulation to get through Phase 2. “We've been ...

Viking's key asset remains VK2735. This dual GLP-1/GIP agonist produced encouraging Phase 2 trial results in 2024 and soon will enter Phase 3 development. VK2735 has potential competitive ...